Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Fiche publication
Date publication
janvier 2019
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Dr MOUILLET Guillaume
Tous les auteurs :
Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L
Lien Pubmed
Résumé
Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of care for naïve patients with intermediate or poor risk prognosis (International mRCC Database Consortium). The efficacy of subsequent vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) after nivolumab-ipilimumab failure remains unclear.
Mots clés
Immunotherapy, Ipilimumab, Metastatic renal cell carcinomas, Nivolumab, Outcomes, Second-line tyrosine kinase inhibitors
Référence
Eur. J. Cancer. 2019 Jan 4;108:33-40